Articles related to CLINICAL TRIALS

The FDA has withdrawn approval for infigratinib in advanced cholangiocarcinoma following Helsinn Healthcare SA’s request, citing recruitment difficulties for a confirmatory trial.

A recent phase 3 trial demonstrates that a combination therapy of belantamab mafodotin, bortezomib, and dexamethasone leads to significantly longer progression-free survival in patients with relapsed or refractory multiple myeloma compared to a regimen including daratumumab.

In a phase 2 study of patients with locally advanced mismatch repair–deficient colon cancer, treatment with neoadjuvant nivolumab plus ipilimumab resulted in a 98% pathological response rate and a 68% pathological complete response rate, with no recurrence of disease observed over a median follow-up of 26 months.

In a phase 3 trial, osimertinib significantly improved median progression-free survival to 39.1 months in patients with unresectable stage III EGFR-mutated NSCLC following chemoradiotherapy, compared to 5.6 months with placebo.

The 2024 ASCO Annual Meeting reveals critical updates on lung and blood cancers, including promising phase 3 trial results and the innovative use of AI to reengage marginalized patients in cancer care.

In a recent phase 3 trial, asciminib has shown superior efficacy and safety in newly diagnosed chronic myeloid leukemia patients, achieving a higher major molecular response rate at week 48 compared to traditional tyrosine kinase inhibitors.